ATE304863T1 - Erythropoietin formulierungen des mehrfachdosis- typs - Google Patents

Erythropoietin formulierungen des mehrfachdosis- typs

Info

Publication number
ATE304863T1
ATE304863T1 AT00960177T AT00960177T ATE304863T1 AT E304863 T1 ATE304863 T1 AT E304863T1 AT 00960177 T AT00960177 T AT 00960177T AT 00960177 T AT00960177 T AT 00960177T AT E304863 T1 ATE304863 T1 AT E304863T1
Authority
AT
Austria
Prior art keywords
erythropoietin
dose type
type formulations
formulations
dose
Prior art date
Application number
AT00960177T
Other languages
German (de)
English (en)
Inventor
Atef Gayed
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE304863T1 publication Critical patent/ATE304863T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT00960177T 1999-07-22 2000-07-21 Erythropoietin formulierungen des mehrfachdosis- typs ATE304863T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19821699P 1999-07-22 1999-07-22
PCT/US2000/040446 WO2001007075A2 (en) 1999-07-22 2000-07-21 Multi-dose erythropoietin formulations

Publications (1)

Publication Number Publication Date
ATE304863T1 true ATE304863T1 (de) 2005-10-15

Family

ID=22732468

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00960177T ATE304863T1 (de) 1999-07-22 2000-07-21 Erythropoietin formulierungen des mehrfachdosis- typs

Country Status (25)

Country Link
US (1) US7432360B2 (enExample)
EP (1) EP1200115B9 (enExample)
JP (1) JP2003517462A (enExample)
KR (1) KR100693263B1 (enExample)
CN (2) CN1371284A (enExample)
AT (1) ATE304863T1 (enExample)
AU (1) AU777397B2 (enExample)
BR (1) BR0012667A (enExample)
CA (1) CA2378945C (enExample)
CZ (1) CZ302750B6 (enExample)
DE (1) DE60022759T2 (enExample)
DK (1) DK1200115T3 (enExample)
EA (1) EA006220B1 (enExample)
EE (1) EE200200037A (enExample)
ES (1) ES2248110T3 (enExample)
HK (1) HK1050318A1 (enExample)
HR (1) HRP20020159B1 (enExample)
HU (1) HUP0202246A3 (enExample)
IL (2) IL147755A0 (enExample)
NO (1) NO20020303L (enExample)
NZ (1) NZ516735A (enExample)
PL (1) PL202945B1 (enExample)
RS (1) RS50355B (enExample)
WO (1) WO2001007075A2 (enExample)
ZA (1) ZA200200742B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU4602A (sh) 1999-07-22 2005-06-10 Aventis Pharmaceuticals Inc. Farmaceutske formulacije zaštićene od dejstva mikroorganizama
EP1525889A1 (en) 2000-05-15 2005-04-27 F. Hoffmann-La Roche Ag Liquid pharmaceutical composition containing an erythropoietin derivative
US7148211B2 (en) 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
CA2561222A1 (en) * 2004-03-26 2005-10-20 Janssen Pharmaceutica, N.V. Combination dosing regimen for erythropoietin
US7772182B2 (en) 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
BRPI0606784B1 (pt) * 2005-02-03 2018-07-31 Clariant Produkte (Deutschland) Gmbh Conservantes
JP2011116752A (ja) * 2009-10-29 2011-06-16 Jcr Pharmaceuticals Co Ltd エリスロポエチン含有水性液剤
KR101805087B1 (ko) * 2010-09-16 2017-12-05 주식회사 엘지화학 높은 방부력을 제공하는 오일 주사 제형
AU2016341241B9 (en) * 2015-10-22 2021-11-18 Iltoo Pharma Pharmaceutical compositions of IL-2

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489837A (en) * 1968-07-11 1970-01-13 Leroy J Hyman Synergistic antiseptic composition consisting of 9-aminoacridine hydrochloride and benzethonium chloride
JPS6045849B2 (ja) 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
JPH0651637B2 (ja) * 1985-03-28 1994-07-06 エーザイ株式会社 ペプタイドの吸着防止組成物
US5045529A (en) * 1989-03-27 1991-09-03 Bionostics, Inc. Tonometric fluid for blood gas and co-oximetry instruments
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
CA2050425A1 (en) * 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
JP2532025B2 (ja) * 1993-07-23 1996-09-11 株式会社林原生物化学研究所 新リンホカインｉｉｉを有効成分とする抗腫瘍作用を有するリンホカインの活性増強剤
US5968899A (en) * 1994-06-03 1999-10-19 Tsumura & Co. Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption
WO1997026004A1 (en) * 1996-01-19 1997-07-24 Eli Lilly And Company Obesity protein formulations
WO1998010785A1 (en) * 1996-09-13 1998-03-19 Advanced Medicine Research Institute Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders
JPH1112193A (ja) * 1997-06-19 1999-01-19 Sankyo Co Ltd ヒトカルシトニン含有水溶液製剤
GB9726555D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine

Also Published As

Publication number Publication date
HUP0202246A2 (en) 2002-10-28
EE200200037A (et) 2003-04-15
NO20020303L (no) 2002-03-21
CN1371284A (zh) 2002-09-25
CA2378945A1 (en) 2001-02-01
DE60022759T2 (de) 2006-06-22
ES2248110T3 (es) 2006-03-16
AU7137400A (en) 2001-02-13
IL147755A (en) 2009-11-18
HRP20020159A2 (en) 2003-06-30
CZ302750B6 (cs) 2011-10-19
IL147755A0 (en) 2002-08-14
EP1200115B1 (en) 2005-09-21
NO20020303D0 (no) 2002-01-21
EP1200115A2 (en) 2002-05-02
DE60022759D1 (de) 2006-02-02
CZ2002264A3 (cs) 2002-06-12
EA200200073A1 (ru) 2002-08-29
PL202945B1 (pl) 2009-08-31
HRP20020159B1 (en) 2007-08-31
YU4702A (sh) 2005-06-10
PL353569A1 (en) 2003-12-01
ZA200200742B (en) 2003-06-25
US20050267033A1 (en) 2005-12-01
RS50355B (sr) 2009-11-10
WO2001007075A3 (en) 2001-10-04
DK1200115T3 (da) 2006-01-16
HK1050318A1 (zh) 2003-06-20
AU777397B2 (en) 2004-10-14
KR20020011143A (ko) 2002-02-07
CN101091792A (zh) 2007-12-26
JP2003517462A (ja) 2003-05-27
NZ516735A (en) 2004-01-30
BR0012667A (pt) 2002-07-02
EP1200115B9 (en) 2006-01-18
US7432360B2 (en) 2008-10-07
HUP0202246A3 (en) 2010-01-28
KR100693263B1 (ko) 2007-03-13
WO2001007075A2 (en) 2001-02-01
EA006220B1 (ru) 2005-10-27
CA2378945C (en) 2010-02-23

Similar Documents

Publication Publication Date Title
DK1091975T3 (da) Ny cyclosporin med forbedret aktivitetsprofil
WO2001034646A3 (en) Recombinant gelatins
ATE290382T1 (de) Heterozyklische kalium-kanal inhibitoren
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
ATE304863T1 (de) Erythropoietin formulierungen des mehrfachdosis- typs
TR199800105A2 (xx) Tadlar� kaplanm��, antibakteriyel etkili kinolon t�revlerinin �retimi.
DE60128462D1 (de) Kosmetische Zusammensetzungen
DE69616074D1 (de) Ara-c derivate
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
DE69628458D1 (de) 25-hydroxy-16-ene-26,27-bishome-cholecalceriferol derivate
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
NO20031673L (no) Behandling av kreft
TR200003203T2 (tr) Karboksaldehitin saflaştırılması
DE59803066D1 (de) Substituierte benzyloxyimino-verbindungen
MA24582A1 (fr) Nouveaux derives de 4-hydroxy-2h-1-(thio) pyran-2-ones, leurs preparations et leurs utilisations comme rodonticides.
AR026890A1 (es) Composiciones de tenocitos, preparaciones y utilizaciones
ATE275551T1 (de) Halogenpyrimidine
IT1303556B1 (it) Procedimento di preparazione di composti del tipoarilamminoalchilidenemalonati.
ES2183543T3 (es) Derivado de tiocolchicosida, su preparacion y su aplicacion en terapeutica.
DE50100533D1 (de) Herstellung von 2-ethyl-3-methyl-1,4-diazin
DE69915688D1 (de) Benzonaphtyridin-1,8 derivate
ES1046207Y (es) Corrector de gesticulacion antiarrugas y antiojeras.
NO964935D0 (no) Anvendelse av et egg-basert preparat som antidepressivum
ITNU990009U1 (it) Lozione per capelli.
FI981888A0 (fi) Vesipitoisten aineiden esim. uutteiden saattaminen puuhun

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1200115

Country of ref document: EP

EEIH Change in the person of patent owner